Should sleep apnoea be a specific target of therapy in chronic heart failure?
1University Health Network and Mount Sinai Hospital Division of Cardiology, University of Toronto, Suite 1614, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. john.floras@utoronto.ca
Abstract:
Sleep apnoea is a common and important co-morbidity in heart failure. It affects survival adversely by: (1) causing nocturnal hypoxia and oxidative stress; (2) raising nocturnal and daytime sympathetic activity and blood pressure and blunting vagal tone; and (3) increasing left ventricular transmural pressure (that is, afterload) and myocardial oxygen demand. Although its abolition by positive airway pressure counters these mechanisms of increased cardiovascular risk and augments ejection fraction, this device therapy has not been adopted widely in cardiovascular practice. An adequately powered outcome trial is required to determine whether sleep apnoea should be a specific therapeutic target in heart failure.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Sleep Apnea
The condition is more prevalent among...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure Drugs: β-Blockers

